Sign In
Buy SGTX
$22.47
+0 (+0%)
At Close: Nov 09, 2023
Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A
07:30am, Friday, 09'th Jul 2021
CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded L
Biotech Losers In 2021 That Could Bounce Big In The Second Half
05:02pm, Saturday, 03'rd Jul 2021
Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked a
Sigilon Therapeutics Appoints Brooke Story, M.B.A., to its Board of Directors
07:00am, Wednesday, 16'th Jun 2021
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded L
Sigilon Therapeutics Appoints Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer
04:05pm, Monday, 14'th Jun 2021
CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded L
Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
04:05pm, Monday, 10'th May 2021
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li
Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
07:00am, Thursday, 08'th Apr 2021
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
04:05pm, Thursday, 18'th Mar 2021
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded
Sigilon Therapeutics' Fabry Disease Therapy Receives Orphan Drug Designation In US
09:23am, Friday, 05'th Mar 2021
The FDA has designated Orphan Drug Status to Sigilon Therapeutics Inc's (NASDAQ: SGTX) SIG-007 to treat Fabry disease. It is a rare genetic disorder caused by AGAL deficiency and the accumulation
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
07:00am, Friday, 05'th Mar 2021
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded
Sigilon Therapeutics to Present at Barclays Global Healthcare Conference
07:00am, Thursday, 04'th Mar 2021
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded
BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential
04:05am, Saturday, 30'th Jan 2021
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private i
Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
07:00am, Wednesday, 13'th Jan 2021
CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
07:00am, Thursday, 17'th Dec 2020
Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 Company plans to initiate a Phase 1/2 trial of SIG-005 in patien
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded
